The Rolanette and Berdon Lawrence Bone Disease Program of Texas
Making a Difference in the Fight Against Bone Disease
In the United States today, 10 million individuals suffer from osteoporosis (porous bone), and almost 34 million more are estimated to have low bone mass, placing them at increased risk for osteoporosis. Anyone over the age of 50 is at risk, making osteoporosis a major public health threat.
Recent advances in treatment regimens for breast and prostate cancer have greatly improved patient survival; however, these therapies can weaken bones. Increasingly, patients who are otherwise cured, or whose cancer is successfully managed for years, are developing osteoporosis at an accelerated rate due to cancer treatment.
Bone metastasis, which occurs most often when breast, prostate, lung, kidney and thyroid cancers spread to bones, is one of the most frequent causes of pain in individuals with cancer. Metastasis to bone is the primary cause of death in prostate cancer.
The Rolanette and Berdon Lawrence Bone Disease Program of Texas, a collaborative research, clinical and education program of Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, was established in 2002 to capitalize on the strengths of these two institutions. The Rolanette and Berdon Lawrence Bone Disease Program of Texas seeks to improve basic and translational research of bone diseases and to convert basic science findings to more effective treatment and prevention options.
- Develop bone-forming treatment for all degenerative bone diseases
- Improve prevention and treatment for bone cancer metastasis
- Foster existing collaborations between the two institutions in this area
Upcoming Events and Announcements
Announcing the 201 Scientific Retreat on June 27, 2014, noon to 8:00pm, Marriott Medical Center, Houston Texas. For more information and application instructions, please visit the Scientific Retreat webpage.
Last updated February 11, 2014 (CS)